Stifel Initiates Coverage On NewAmsterdam Pharma Co with Buy Rating, Announces Price Target of $44
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Stifel analyst James Condulis initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy rating and announces Price Target of $44.
Stifel analyst James Condulis initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy rating and announces Price Target of $44.